Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone
News
Optofluidics announces Hexpoint, a new particle analysis system for early stage formulation
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone
Optofluidics announces Hexpoint, a new particle analysis system for early stage formulation